drugset / Trial / NCT02099994
Safety & Immunogenicity of HIV Vaccines in Healthy Kenyan Adults
Phase 1/2
Completed
72 enrolled
University of Oxford
European and Developing Countries Clinical Trials Partnership (EDCTP) · collabIchor Medical Systems Incorporated · collabInternational AIDS Vaccine Initiative · collabKarolinska Institutet · collabUniversity of Nairobi · collab
RandomizedParallel-groupDouble-blindPrevention
Summary
The study is part of a long-term aim to develop an effective HIV-1 vaccine and will evaluate safety and immunogenicity of vaccines focusing T cell responses on the conserved region of the HIV-1 proteome. The vaccines used are pSG2.HIVconsv DNA (D), MVA.HIVconsv (M) and Ad35-GRIN (A), delivered in regimens AM, DDDAM and DeDeDeAM, where e indicates electroporation.
Timeline
- Start
- 2014-03
- Primary completion
- 2015-08
- Completion
- 2015-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ad35-GRIN | Vaccine | 5e+10 unknown | Intramuscular |
| Subject | MVA.HIVconsv | Vaccine | 2e+08 unknown | Intramuscular |
| Subject | pSG2.HIVconsv DNA | Vaccine | 4 mg | Intramuscular |